These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32606807)

  • 21. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
    Ferhanoglu B; Ozbalak M
    Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
    Arabloo J; Azari S; Gorji HA; Rezapour A; Alipour V; Ehsanzadeh SJ
    Eur J Clin Pharmacol; 2023 Nov; 79(11):1443-1452. PubMed ID: 37656182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
    Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
    Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
    Rubinstein PG; Moore PC; Rudek MA; Henry DH; Ramos JC; Ratner L; Reid E; Sharon E; Noy A;
    AIDS; 2018 Mar; 32(5):605-611. PubMed ID: 29280762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
    Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
    Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
    Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
    Vassilakopoulos TP; Liaskas A; Pereyra P; Panayiotidis P; Angelopoulou MK; Gallamini A
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Wang Z; Sun K; Zhu ZM; Zhang P; Yang J; Yang SW; Zheng MQ
    Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2941-2948. PubMed ID: 33877657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
    Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
    Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
    Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies.
    Vassilakopoulos TP; Chatzidimitriou C; Asimakopoulos JV; Arapaki M; Tzoras E; Angelopoulou MK; Konstantopoulos K
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31362369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Management of older patients with Hodgkin lymphoma: implications of S1826.
    McKenna M; Ryu Tiger YK; Rutherford SC; Evens AM
    Semin Hematol; 2024 Aug; 61(4):236-244. PubMed ID: 38945791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
    Eyre TA; Phillips EH; Linton KM; Arumainathan A; Kassam S; Gibb A; Allibone S; Radford J; Peggs K; Burton C; Stewart G; LeDieu R; Booth C; Osborne WL; Miall F; Eyre DW; Ardeshna KM; Collins GP
    Br J Haematol; 2017 Nov; 179(3):471-479. PubMed ID: 28857136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.
    Carlo-Stella C; Ricci F; Dalto S; Mazza R; Malagola M; Patriarca F; Viviani S; Russo D; Giordano L; Castagna L; Corradini P; Santoro A
    Oncologist; 2015 Mar; 20(3):323-8. PubMed ID: 25669663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Initial treatment strategy for classical Hodgkin lymphoma in adults].
    Kusumoto S
    Rinsho Ketsueki; 2021; 62(8):1102-1111. PubMed ID: 34497197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma.
    Lai C; Kandahari AM; Ujjani C
    Blood Lymphat Cancer; 2019; 9():63-71. PubMed ID: 31849558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
    Fornecker LM; Lazarovici J; Aurer I; Casasnovas RO; Gac AC; Bonnet C; Bouabdallah K; Feugier P; Specht L; Molina L; Touati M; Borel C; Stamatoullas A; Nicolas-Virelizier E; Pascal L; Lugtenburg P; Di Renzo N; Vander Borght T; Traverse-Glehen A; Dartigues P; Hutchings M; Versari A; Meignan M; Federico M; André M;
    J Clin Oncol; 2023 Jan; 41(2):327-335. PubMed ID: 35867960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.